New low-toxic candidate drug PTC596 is expected to treat pancreatic cancer

Pancreatic cancer is one of the most lethal types of cancer, and pancreatic tumors are supplemented with a thick layer of connective tissue (matrix, stroma), which hardens the tumor and provides protective effects to tumor tissue;study, researchers found that a long-standing low toxicity may have the potential to be effective in treating pancreatic cancer, and that in order for pancreatic cancer drugs to work effectively, they must stay around the tumor long enough to pass through the matrix structure and accumulate at the tumor site;, researchers identified a new type of drug candidate, an experimental compound called PTC596, which has potentialantional antitumor activity in mouse and human pancreatic cancer cells, and has a long-lasting drug half-life that can invade and attack the special structure-molecular pumps that many cancer cells use to drain the drug, meaning that any number of drugs can effectively target malignant cells through a barrierresearchers then combined PTC596 with the drug Gisitabin to analyze its effect on genetically engineered mice that carry malignant pancreatic cancer and are resistant to chemotherapy, and the use of a combination of two drugs increased the survival of mice by three times compared to single drug therapy, which is very exciting because any extended survival therapy in the gold-standard mouse model is very rareThe researchers then analyzed the effects of PTC596 combined albumin in combination with nab-paclitaxel in mouse models that treated human pancreatic cancer, a new combination that showed higher efficiency and promoted tumor atrophybased on drug safety characteristics and related research findings, researchers are confident that PTC596 will be combined with standardized therapies to treat pancreatic cancer patientsThe researchers say PTC596 can block the formation of cancer cell microtubule, an important protein network that is primarily involved in cell division and the transport of nutrients, PTC596 may be able to work in concert with albumin binding to yew alcohol, while albumin binding to yew alcohol is another microtube blockerfinal researcher Olive said that combining different microtube inhibitors or playing an important role in tumor biology research will further study the development of new combination therapies to treat pancreatic canceroriginal origins: Jaime AEberle-Singh, Irina Sagalovskiy, HCarlo Maurer, et alEffective Delivery of a Microtubule Polymer Synergize Steins, Martin Regimes In Models of The Stal Adenocarcinoma, Clinical Cancer Research (2019)DOI: 10.1158/1078-0432.CCR-18-3281Original Title: Clin Cancer Res: A New Drug Candidate For Low Toxic Persistence Promises to Completely Treat Pancreatic Cancer